<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915577</url>
  </required_header>
  <id_info>
    <org_study_id>C-872</org_study_id>
    <nct_id>NCT00915577</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe</brief_title>
  <official_title>An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine patient satisfaction with the single-use autoinjector for the delivery of
      pre-filled Avonex syringe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled AVONEX® syringe</measure>
    <time_frame>The study duration is 8 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1st Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manual injection with pre-filled syringe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-use autoinjector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-use autoinjector with Avonex pre-filled syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>30mcg, IM once-a-week</description>
    <arm_group_label>1st Injection</arm_group_label>
    <other_name>Avonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single-use autoinjector</intervention_name>
    <description>Single-use autoinjector with Avonex 30mcg pre-filled syringe</description>
    <arm_group_label>Single-use autoinjector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be using liquid AVONEX® to treat MS. In addition, the subject must be on liquid
             AVONEX® for 12 weeks prior to the Screening Visit.

          -  Must have a BMI of 19 to 28 kg/m², inclusive, and a minimum body weight of 50 kg at
             Screening.

          -  Must be able to physically demonstrate use of the device and be able to
             self-administer all injections.

          -  Must be English speaking.

          -  Must be able to understand and comply with the protocol.

        Exclusion Criteria:

          -  Abnormal screening or screening blood tests determined to be clinically significant by
             the investigator for: white blood count (WBC) or differential, platelet count,
             hemoglobin, serum creatinine, bilirubin, alanine transaminase (ALT) aspartate
             transaminase (AST), prothrombin time (PT).

          -  Known sensitivity to dry natural rubber.

          -  Treatment with other agents to treat MS symptoms or underlying disease as specified in
             the protocol.

          -  History of severe allergic or anaphylactic reactions.

          -  History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, and
             aspirin that would preclude the use of at least one of these during the study.

          -  Serious local infection

        Other inclusion and exclusion criteria apply as per Biogen Idec Protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen-Idec Investigator</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>June 5, 2009</last_update_submitted>
  <last_update_submitted_qc>June 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>interferon beta-1a</keyword>
  <keyword>Avonex</keyword>
  <keyword>liquid Avonex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

